Picture Stier Group MIXiii Lifescience Healthtech Conference 650x100px

Financing › Details

908 Devices–SEVERAL: investment, 202012 IPO $130m+$19.5m net $136.6m with 6.5m+975k shares common stock at $20/share at Nasdaq Global Market

	Period	2020-12-18
	Region	United States (USA)
	Predecessor	908 Devices–SEVERAL: investment, 201904 financing round Series E $17.5m led by new investor Northpond Ventures
	Money taker	908 Devices Inc. (Nasdaq: MASS)
	Group	908 Devices (Group)
	Money source	SEVERAL
	Product	high-pressure mass spectrometry (HPMS™ technology)
	Product 2	investment banking

908 Devices, Inc.. (12/18/20). "Press Release: 908 Devices Announces Pricing of Initial Public Offering".

908 Devices Inc., a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the pricing of its upsized initial public offering of shares of its common stock, with 6,500,000 shares being offered by the Company at a public offering price of $20.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 975,000 shares of common stock from the Company at the public offering price. The shares are expected to begin trading on the Nasdaq Global Market on December 18, 2020 under the ticker symbol “MASS.” The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by 908 Devices are expected to be $130.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on December 22, 2020, subject to the satisfaction of customary closing conditions.

Cowen and SVB Leerink acted as lead book-running managers for the proposed offering. William Blair and Stifel acted as book-running managers for the proposed offering.

A registration statement on Form S-1 relating to the shares sold in the initial public offering has been filed with the Securities and Exchange Commission and became effective on December 17, 2020. The offering will be made only by means of a prospectus, copies of which may be obtained from: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 833-297-2926, or by email at PostSaleManualRequests@broadridge.com; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02120, telephone: 1-800-808-7525, ext. 6132, or by email at syndicate@svbleerink.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Record changed: 2022-11-12